Next Article in Journal
A Biological Approach to the Synthesis of Silver Nanoparticles with Streptomyces sp JAR1 and its Antimicrobial Activity
Previous Article in Journal
Preparation and In Vitro/Ex Vivo Evaluation of Moxifloxacin-Loaded PLGA Nanosuspensions for Ophthalmic Application
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Oral Immunization Against Candidiasis Using Lactobacillus casei Displaying Enolase 1 from Candida albicans

by
Seiji SHIBASAKI
1,*,
Miki KARASAKI
1,
Senji TAFUKU
2,
Wataru AOKI
3,
Tomomitsu SEWAKI
2 and
Mitsuyoshi UEDA
3
1
General Education Center and Graduate School of Pharmacy, Hyogo University of Health Sciences, 1-3-6 Minatojima, Chuo-ku, Kobe 650-8530, Japan
2
Genolac BL Corporation, Okinawa Industry Support Center 4F, 1831-1, Oroku, Naha City, Okinawa 901-0152, Japan
3
Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawaoiwakecho, Sakyo-ku, Kyoto 606-8502, Japan
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2014, 82(3), 697-708; https://doi.org/10.3797/scipharm.1404-07
Submission received: 19 April 2014 / Accepted: 23 July 2014 / Published: 23 July 2014

Abstract

Candidiasis is a common fungal infection that is prevalent in immunocompro-mised individuals. In this study, an oral vaccine against Candida albicans was developed by using the molecular display approach. Enolase 1 protein (Eno1p) of C. albicans was expressed on the Lactobacillus casei cell surface by using poly-gamma-glutamic acid synthetase complex A from Bacillus subtilis as an anchoring protein. The Eno1p-displaying L. casei cells were used to immunize mice, which were later challenged with a lethal dose of C. albicans. The data indicated that the vaccine elicited a strong IgG response and increased the survival rate of the vaccinated mice. Furthermore, L. casei acted as a potent adjuvant and induced high antibody titers that were comparable to those induced by strong adjuvants such as the cholera toxin. Overall, the molecular display method can be used to rapidly develop vaccines that can be conveniently administered and require minimal processing.
Keywords: Eno1p; Candida albicans; Lactococcus casei; Molecular display technology; Candidiasis Eno1p; Candida albicans; Lactococcus casei; Molecular display technology; Candidiasis

Share and Cite

MDPI and ACS Style

SHIBASAKI, S.; KARASAKI, M.; TAFUKU, S.; AOKI, W.; SEWAKI, T.; UEDA, M. Oral Immunization Against Candidiasis Using Lactobacillus casei Displaying Enolase 1 from Candida albicans. Sci. Pharm. 2014, 82, 697-708. https://doi.org/10.3797/scipharm.1404-07

AMA Style

SHIBASAKI S, KARASAKI M, TAFUKU S, AOKI W, SEWAKI T, UEDA M. Oral Immunization Against Candidiasis Using Lactobacillus casei Displaying Enolase 1 from Candida albicans. Scientia Pharmaceutica. 2014; 82(3):697-708. https://doi.org/10.3797/scipharm.1404-07

Chicago/Turabian Style

SHIBASAKI, Seiji, Miki KARASAKI, Senji TAFUKU, Wataru AOKI, Tomomitsu SEWAKI, and Mitsuyoshi UEDA. 2014. "Oral Immunization Against Candidiasis Using Lactobacillus casei Displaying Enolase 1 from Candida albicans" Scientia Pharmaceutica 82, no. 3: 697-708. https://doi.org/10.3797/scipharm.1404-07

Article Metrics

Back to TopTop